A brand new, more effective shingles vaccine has been approved by the U.S. Food as well as Drug Administration.
The brand new vaccine through GlaxoSmithKline will be the second shingles vaccine available inside U.S. market. The additional is actually through Merck as well as was introduced in 2006, the Associated Press reported.
Shingles is actually a painful condition caused by the chickenpox virus. Anyone who’s had chickenpox carries the virus of which causes shingles.
A study funded by Glaxo found of which the company’s Shingrix vaccine prevented shingles in about 0 percent of people. Merck’s Zostavax vaccine is actually about 50 percent effective, the AP reported.
Shingrix will cost $280 for the required two shots. Zostavax costs $223. Most insurance plans cover the vaccination.
Both vaccines are for adults 50 as well as older, although the Centers for Disease Control as well as Prevention recommends vaccination for people 60 as well as older, partly because vaccination loses effectiveness over time, the AP reported.
Copyright © 2017 HealthDay. All rights reserved.
Subscribe to MedicineNet’s General Health Newsletter
Incoming search terms:
- branded vaccine registration to FDa